Skip to main content
TipRanks
Go Ultimate75% OFF

Kontigo Care AB (KONT) AI Stock Analysis

0 Followers
SE:KONT

Kontigo Care AB

(Nasdaq OMX AB:KONT)

Select Model
Rating:51Neutral
Price Target:SEK 1.50â–²(26.58% Upside)
Action:reiterated
Date:10/20/26

The overall score is constrained by weak technicals and a lack of profitability, which heavily impacts valuation. The company's strong revenue growth and pristine, debt-free balance sheet provide a foundation, but until operating leverage improves and the stock price stabilizes, the risk-reward remains unfavorable.

Positive Factors
Revenue ReaccelerationTTM revenue growth of 42.5% signals renewed demand for the company’s monitoring solutions after the 2025 decline. If sustained, this expansion can improve operating leverage, deepen provider adoption, and support a larger recurring-revenue base over the next several quarters.
Negative Factors
Persistent LossesDespite renewed revenue growth, the company remains slightly loss-making at both operating and net levels in TTM. The return from profitability in 2022–2024 to losses in 2025 and TTM shows earnings conversion is not yet dependable, weakening confidence in near-term self-sustaining growth.

Kontigo Care AB (KONT) vs. iShares MSCI Sweden ETF (EWD)

-50%-40%-30%-20%-10%0%10%20%30%SE:KONT-42.48%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 41.77M
Dividend Yield
―
Average Volume (3M)
23.57K
Price to Earnings (P/E)
-42.4
Beta (1Y)
-0.03
Revenue Growth
0.97%
EPS Growth
41.35%
Country
Sweden
Employees
11
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Kontigo Care AB Business Overview & Revenue Model

Company Description

Kontigo Care AB (publ) specializes in delivering healthcare solutions aimed at addressing addiction issues within Sweden. Their product portfolio includes Previct Alcohol, a digital medical device designed to manage alcohol dependence, and Previct Ga...

How the Company Makes Money

Kontigo Care AB makes money primarily by selling its remote monitoring solutions to organizational customers (e.g., healthcare providers, clinics, municipalities, or other entities running treatment/rehabilitation programs). Revenue is generally gene...

Kontigo Care AB Financial Statement Overview

Summary

Strong revenue growth (+42.5%) and high gross margins (84.2%) are offset by persistent net losses and negative free cash flow. The debt-free balance sheet is a major strength, but the inability to convert growth into profit is a significant concern.

Income Statement

62Positive

Balance Sheet

78Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue29.56M29.13M30.24M28.95M28.43M24.54M
Gross Profit24.89M36.56M40.08M43.73M28.24M24.16M
EBITDA5.19M3.57M5.07M1.79M4.13M90.88K
Net Income-981.00K-2.07M775.00K212.00K2.90M-1.20M
Balance Sheet
Total Assets58.49M62.12M67.74M49.77M31.39M29.20M
Cash, Cash Equivalents and Short-Term Investments13.24M14.95M21.86M9.85M5.74M8.48M
Total Debt003.67M5.95M01,078
Total Liabilities8.79M11.62M15.42M19.05M9.98M10.74M
Stockholders Equity49.70M50.50M52.32M30.72M21.40M18.46M
Cash Flow
Free Cash Flow-4.45M-3.24M-5.61M-9.07M-2.20M272.26K
Operating Cash Flow4.00M5.00M4.61M5.97M7.30M4.61M
Investing Cash Flow-4.61M-8.24M-10.70M-16.73M-9.50M-4.34M
Financing Cash Flow-2.39M-3.67M18.11M14.87M-540.00K3.27M

Kontigo Care AB Technical Analysis

Technical Analysis SentimentNegative
Last Price1.19

Price Trends

50DMA1.26Negative
100DMA1.37Negative
200DMA1.48Negative

Market Momentum

MACD-0.00Positive
RSI43.15Neutral
STOCH32.50Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:KONT, the sentiment is Negative. The current price of 1.19 is below the 20-day moving average (MA) of 1.32, below the 50-day MA of 1.26, and below the 200-day MA of 1.48, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 43.15 is Neutral, neither overbought nor oversold. The STOCH value of 32.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:KONT.

Kontigo Care AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:KONT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:PTRKSE:PTRK59NeutralSEK 171.55M-1.95――-10.30%-11.59%
SE:SEZISE:SEZI55NeutralSEK 510.16M-5.23-35.44%―18.56%28.11%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:MNTCSE:MNTC51NeutralSEK 461.26M-24.43-15.00%―11.18%60.51%
SE:KONTSE:KONT51NeutralSEK 41.77M-42.41-1.94%―0.97%41.35%
SE:AINOSE:AINO43NeutralSEK 36.00M-3.44105.04%―-10.72%-77.78%
SE:QLIFESE:QLIFE37UnderperformSEK 25.44M-0.651852.00%―142.55%73.84%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%SE:KONTSE:SEZISE:QLIFESE:AINOSE:MNTCSE:PTRKDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:KONT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:KONTKontigo Care AB1.19-0.86-42.20%
SE:SEZISenzime AB3.25-1.81-35.87%
SE:QLIFEQlife Holding AB0.88-0.47-34.69%
SE:AINOAino Health AB0.18-0.03-15.38%
SE:MNTCMentice AB16.401.308.61%
SE:PTRKPhysitrack Limited10.55-4.35-29.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 20, 2026